Evidence map›Paper›PMID 27959900›Full record

ArticlePloS one2016

Genomic Profile of Chronic Lymphocytic Leukemia in Korea Identified by Targeted Sequencing.

Jung-Ah Kim, Byungjin Hwang, Si Nae Park, Sunghoon Huh, Kyongok Im, Sungbin Choi, Hye Yoon Chung, JooRyung Huh, Eul-Ju Seo, Je-Hwan Lee and 2 more

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04059081 (A Prospective Cohort of Obinutuzumab and Chlorambucil), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04059081 phase2unknown statusnot on this mapstarted 2019, after this paper: background citation

A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment

TypeinterventionalSponsorDeok-Hwan YangRan2019 to 2022Enrolled31ConditionsChronic Lymphocytic LeukemiaArmsObinutuzumab
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. The roles of KLHL family members in human cancers.American journal of cancer research · 2022
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. BCOR involvement in cancer.Epigenomics · 2019
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Jung-Ah KimDepartment of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.ORCID http://orcid.org/0000-0001-6934-1987
Byungjin HwangDepartment of Chemistry, Yonsei University, Seoul, Korea.
Si Nae ParkCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Sunghoon HuhDepartment of Chemistry, Yonsei University, Seoul, Korea.
Kyongok ImCancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Sungbin ChoiBachelor of Science, University of British Columbia, Vancouver, Canada.
Hye Yoon ChungDepartment of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
JooRyung HuhDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Eul-Ju SeoDepartment of Laboratory Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Je-Hwan LeeDepartment of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Duhee BangDepartment of Chemistry, Yonsei University, Seoul, Korea.
Dong Soon LeeDepartment of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
Seoul National University · KRUlsan College · KRYonsei University · KRUniversity of British Columbia · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is extremely rare in Asian countries and there has been one report on genetic changes for 5 genes (TP53, SF3B1, NOTCH1, MYD88, and BIRC3) by Sanger sequencing in Chinese CLL. Yet studies of CLL in Asian countries using Next generation sequencing have not been reported. We aimed to characterize the genomic profiles of Korean CLL and to find out ethnic differences in somatic mutations with prognostic implications. We performed targeted sequencing for 87 gene panel using next-generation sequencing along with G-banding and fluorescent in situ hybridization (FISH) for chromosome 12, 13q14.3 deletion, 17p13 deletion, and 11q22 deletion. Overall, 36 out of 48 patients (75%) harbored at least one mutation and mean number of mutation per patient was 1.6 (range 0-6). Aberrant karyotypes were observed in 30.4% by G-banding and 66.7% by FISH. Most recurrent mutation (>10% frequency) was ATM (20.8%) followed by TP53 (14.6%), SF3B1 (10.4%), KLHL6 (8.3%), and BCOR (6.25%). Mutations of MYD88 was associated with moderate adverse prognosis by multiple comparisons (P = 0.055). Mutation frequencies of MYD88, SAMHD1, EGR2, DDX3X, ZMYM3, and MED12 showed similar incidence with Caucasians, while mutation frequencies of ATM, TP53, KLHL6, BCOR and CDKN2A tend to be higher in Koreans than in Caucasians. Especially, ATM mutation showed 1.5 fold higher incidence than Caucasians, while mutation frequencies of SF3B1, NOTCH1, CHD2 and POT1 tend to be lower in Koreans than in Caucasians. However, mutation frequencies between Caucasians and Koreans were not significantly different statistically, probably due to low number of patients. Collectively, mutational profile and adverse prognostic genes in Korean CLL were different from those of Caucasians, suggesting an ethnic difference, while profile of cytogenetic aberrations was similar to those of Caucasians.

Indexed as

Genetic LociGenome, HumanMutationAdultAgedAged, 80 and overAsian PeopleCase-Control StudiesChromosome AberrationsFemaleHumansLeukemia, LymphoidMaleMiddle AgedMutation RateRepublic of Korea

Identifiers

PMID27959900
PMCPMC5154520
OpenAlexW2564248509

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.